<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="209216">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00364273</url>
  </required_header>
  <id_info>
    <org_study_id>B2F104300</org_study_id>
    <nct_id>NCT00364273</nct_id>
  </id_info>
  <brief_title>GSK159802 In Healthy Male Subjects And Asthmatics</brief_title>
  <official_title>A Randomised, Double-blind, Placebo Controlled Study to Examine the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single Inhaled Dry Powder Doses of GSK159802 in Healthy Male Subjects and Asthmatics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      GSK159802 is a potent, inhaled, long acting selective beta-2-receptor agonist (LABA), which
      is being developed for once daily treatment of asthma and COPD as part of a combination
      product with a once daily inhaled corticosteroid and also as a standalone product for the
      treatment of COPD. Stimulation of the beta-2-agonist in the lung mainly relaxes bronchial
      smooth muscle cells which results in bronchodilation. Unwanted systemic side effects related
      with beta-2-agonist treatment such as tachycardia, tremor, hyperglycemia and hypokalemia are
      limited by local administration and also tend to show tachyphylaxis.

      The LABAs that are currently available (e.g., salmeterol, formoterol) require twice-daily
      administration, given their duration of action. Therefore, there is significant opportunity
      for a once-daily inhaled medication to improve patient compliance and overall disease
      management by providing sustained, 24-hour bronchodilation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">July 2006</completion_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double-Blind</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety &amp; tolerability of single inhaled doses of GSK159802.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>sGaw (Cohorts 1 and 2 only) and FEV1 Systemic &amp; urine pharmacokinetics of GSK159802 and SKF-91300 Heart rate, potassium, glucose, 12-lead ECG &amp; blood pressure</measure>
  </secondary_outcome>
  <enrollment type="Actual">45</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK159802</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Body mass index within the range 18.5-29.9 (kg/m2)

          -  Current non-smokers who have not used any tobacco products in the 6-month period
             preceding the screening visit and have a pack history of &lt; 10 pack years.

        Additional criteria for Cohorts 2 and 3 only (Asthmatic Patients):

          -  Subjects with a documented history of mild to moderate asthma, with the exclusion of
             other significant pulmonary disease

          -  Subjects with clinically stable asthma within the 4 weeks preceding the screening
             visit and with a screening pre-bronchodilator FEV1 greater than 60% and less than 90%
             predicted.

        During the screening visit, subjects must demonstrate the presence of reversible airway
        disease, defined as an increase in FEV1 of &gt; or equal to 12.0% over baseline and an
        absolute change of &gt; or equal to 300 mL within 30 minutes following 400 mcg salbutamol.

        Exclusion criteria:

          -  Any clinically relevant abnormality

          -  Subjects who have a screening haemoglobin values &lt; 11 g/dL

          -  The subject has participated in a clinical study with a New Chemical Entity (NCE)
             within the past 112 days or a clinical study with any other drug during the previous
             84 days

          -  Subjects with known hypersensitivity to salmeterol or salbutamol or any ingredients
             in their preparations.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <state>Lancashire</state>
        <zip>M23 9LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 17, 2016</lastchanged_date>
  <firstreceived_date>August 11, 2006</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>B2F104300</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>B2F104300</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>B2F104300</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>B2F104300</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>B2F104300</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>B2F104300</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>B2F104300</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
